FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2201839959> ?p ?o ?g. }

• W2201839959 endingPage "111" @default.
• W2201839959 startingPage "104" @default.
• W2201839959 abstract "P-glycoprotein (P-gp)-mediated brain efflux of xenobiotics is a well-known process, which may result in suboptimal target engagement and consequently reduced efficacy of drugs exerting their therapeutic effects in the central nervous system. In the present study the role of P-gp in transport across the blood-brain barrier (BBB) was investigated with a series of newer antidepressants (levomilnacipran, vilazodone and vortioxetine) and a control substrate (escitalopram) using P-gp knock-out (KO) and P-gp competent wild-type (WT) mice. Brain and plasma exposure time-courses were measured after an acute subcutaneous dose and at steady-state obtained after subcutaneous drug infusion by osmotic minipumps. Following acute dosing, the brain-to-plasma KO/WT exposure enhancement ratios ((AUCbrain ko/AUCplasma ko)/(AUCbrain WT/AUCplasma WT)) were 5.8 (levomilnacipran), 5.4 (vilazodone), 3.1 (escitalopram) and 0.9 (vortioxetine), respectively. At steady-state, assessment of Kp,uu (unbound brain concentrations/unbound plasma concentrations) revealed a restriction in the brain distribution in WT mice for all compounds except vortioxetine. Levomilnacipran exhibited the most pronounced efflux with a Kp,uu-value of 0.038 in WT mice which was increased to 0.37 in KO mice. Based on both the acute and steady-state distribution data, the results suggest that levomilnacipran, vilazodone and escitalopram are susceptible to P-gp mediated efflux at the BBB in vivo in mice, whereas vortioxetine was practically devoid of being affected by P-gp in vivo. The functional impact of the drug transport-controlling role of P-gp at the BBB was demonstrated by in vivo cortical serotonin transporter occupancy of vilazodone, which exhibited a 20-fold higher plasma EC50 in WT mice compared to KOs." @default.
• W2201839959 created "2016-06-24" @default.
• W2201839959 creator A5018662511 @default.
• W2201839959 creator A5028936915 @default.
• W2201839959 creator A5074909311 @default.
• W2201839959 date "2016-04-01" @default.
• W2201839959 modified "2023-10-12" @default.
• W2201839959 title "P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo" @default.
• W2201839959 cites W1501777540 @default.
• W2201839959 cites W1963859579 @default.
• W2201839959 cites W1973544766 @default.
• W2201839959 cites W1981625417 @default.
• W2201839959 cites W1987980474 @default.
• W2201839959 cites W1990376788 @default.
• W2201839959 cites W1992459928 @default.
• W2201839959 cites W1998748649 @default.
• W2201839959 cites W2003160092 @default.
• W2201839959 cites W2005447377 @default.
• W2201839959 cites W2009966911 @default.
• W2201839959 cites W2020724953 @default.
• W2201839959 cites W2021097680 @default.
• W2201839959 cites W2028243383 @default.
• W2201839959 cites W2029415007 @default.
• W2201839959 cites W2044392411 @default.
• W2201839959 cites W2046826638 @default.
• W2201839959 cites W2049892216 @default.
• W2201839959 cites W2051372812 @default.
• W2201839959 cites W2053657477 @default.
• W2201839959 cites W2054489505 @default.
• W2201839959 cites W2058780134 @default.
• W2201839959 cites W2064263196 @default.
• W2201839959 cites W2072981607 @default.
• W2201839959 cites W2073985064 @default.
• W2201839959 cites W2079429358 @default.
• W2201839959 cites W2108141803 @default.
• W2201839959 cites W2108147692 @default.
• W2201839959 cites W2108982217 @default.
• W2201839959 cites W2109937255 @default.
• W2201839959 cites W2110057699 @default.
• W2201839959 cites W2110475445 @default.
• W2201839959 cites W2132134960 @default.
• W2201839959 cites W2136487679 @default.
• W2201839959 cites W2143242847 @default.
• W2201839959 cites W2143535850 @default.
• W2201839959 cites W2151592453 @default.
• W2201839959 cites W2162611158 @default.
• W2201839959 cites W2163095058 @default.
• W2201839959 cites W2167161304 @default.
• W2201839959 cites W2397510889 @default.
• W2201839959 doi "https://doi.org/10.1016/j.neuropharm.2015.12.009" @default.
• W2201839959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26700248" @default.
• W2201839959 hasPublicationYear "2016" @default.
• W2201839959 type Work @default.
• W2201839959 sameAs 2201839959 @default.
• W2201839959 citedByCount "26" @default.
• W2201839959 countsByYear W22018399592016 @default.
• W2201839959 countsByYear W22018399592017 @default.
• W2201839959 countsByYear W22018399592018 @default.
• W2201839959 countsByYear W22018399592019 @default.
• W2201839959 countsByYear W22018399592020 @default.
• W2201839959 countsByYear W22018399592021 @default.
• W2201839959 countsByYear W22018399592022 @default.
• W2201839959 countsByYear W22018399592023 @default.
• W2201839959 crossrefType "journal-article" @default.
• W2201839959 hasAuthorship W2201839959A5018662511 @default.
• W2201839959 hasAuthorship W2201839959A5028936915 @default.
• W2201839959 hasAuthorship W2201839959A5074909311 @default.
• W2201839959 hasConcept C133936738 @default.
• W2201839959 hasConcept C134018914 @default.
• W2201839959 hasConcept C150903083 @default.
• W2201839959 hasConcept C185592680 @default.
• W2201839959 hasConcept C200082930 @default.
• W2201839959 hasConcept C207001950 @default.
• W2201839959 hasConcept C2778034309 @default.
• W2201839959 hasConcept C2778402981 @default.
• W2201839959 hasConcept C2778707650 @default.
• W2201839959 hasConcept C2779177272 @default.
• W2201839959 hasConcept C2779583969 @default.
• W2201839959 hasConcept C2781161787 @default.
• W2201839959 hasConcept C501593827 @default.
• W2201839959 hasConcept C529278444 @default.
• W2201839959 hasConcept C55493867 @default.
• W2201839959 hasConcept C71924100 @default.
• W2201839959 hasConcept C86803240 @default.
• W2201839959 hasConcept C98274493 @default.
• W2201839959 hasConceptScore W2201839959C133936738 @default.
• W2201839959 hasConceptScore W2201839959C134018914 @default.
• W2201839959 hasConceptScore W2201839959C150903083 @default.
• W2201839959 hasConceptScore W2201839959C185592680 @default.
• W2201839959 hasConceptScore W2201839959C200082930 @default.
• W2201839959 hasConceptScore W2201839959C207001950 @default.
• W2201839959 hasConceptScore W2201839959C2778034309 @default.
• W2201839959 hasConceptScore W2201839959C2778402981 @default.
• W2201839959 hasConceptScore W2201839959C2778707650 @default.
• W2201839959 hasConceptScore W2201839959C2779177272 @default.
• W2201839959 hasConceptScore W2201839959C2779583969 @default.
• W2201839959 hasConceptScore W2201839959C2781161787 @default.
• W2201839959 hasConceptScore W2201839959C501593827 @default.

• next